Is Tvardi Therapeutics, Inc. (TVRD) overvalued? · rev $7.1M
Tvardi Therapeutics, Inc. (TVRD) is a biotechnology company listed on US.
This page asks whether Tvardi Therapeutics, Inc. (TVRD) looks expensive on cached numbers — not a short thesis.
Latest reported TVRD revenue for 2024-12-31 was $7.1M. Net income was -$70.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. TVRD currently screens at market cap $0.
TVRD currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TVRD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TVRD stock page for the full model, not this heading.
Not investment advice.